Q-omics provides the consensus-scored VXN profile across patient tissues and cancer cell-line models. VXN expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, VXN is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, VXN RNA expression shows 17,283 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where VXN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VXN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VXN survival associations across molecular data types. VXN RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VXN RNA expression–survival associations across cancer types. High VXN expression shows unfavorable associations in UCEC, LAML and DLBC, but favorable associations in LUAD, LIHC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for VXN RNA expression.
This table summarizes VXN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VXN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VXN shows lower tumor expression in COAD, LUSC, UCEC, BLCA and STAD and higher tumor expression in KIRC. The KIRC box plot shows higher VXN RNA expression in tumor versus normal tissue (log2 FC = +1.420, t-test p < 0.001).
This table shows molecular features associated with VXN in patient tissues and cancer cell lines. In patient samples, VXN shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VXN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and STOMACH.
